BCRC. In 1974 the clinical unit of the BCRC moved to the University of Maryland Medical Center, and in 1976 the BCRC laboratories moved into the University of Maryland School of Medicine. The center remained an intramural NCI program under contractual arrangement between NCI and the University of Maryland at Baltimore. In 1978 its name was changed to the Baltimore Cancer Research Program (BCRP). From its inception, the BCRP was very active in clinical research with protocols developed by BCRP staff and via national groups such as the Cancer and Leukemia Group B (CALGB). The BCRP was also very active in basic and applied laboratory research in pharmacology, enzymology, immunology, and microbiology. In 1981 the National Cancer Institute divested the Baltimore Cancer Research Program from the federal government, and the University of Maryland School of Medicine and the Medical Center established the University of Maryland Cancer Center. In 1996, the center's name was changed to the Marlene and Stewart Greenebaum Cancer Center (UMGCC) in recognition of a $10 million gift by its namesake benefactors: Baltimore philanthropists Marlene and Stewart Greenebaum and in 2008, was selected to be a designated cancer center by the NCI becoming 1 of 64 centers throughout the United States to have earned that distinction. After earning the NCI's highest designation of Comprehensive Cancer Center, the university changed the center's name and , has been called the University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center. Notable Clinical and Research Activities UM Professor of pharmacology Angela H. Brodie, Ph.D., pioneered the development of a new class of breast cancer drugs, aromatase inhibitors, now the standard of care for women worldwide. UM Radiation oncology physicists developed direct aperture optimization (DAO), an IMRT planning technique that dramatically reduces treatment time. Research in new drug development and new anti-cancer drugs. Virtually every important drug in use in oncology today has been tested in this program, and the center has contracts in both the public and private sectors with a commitment to clinical and laboratory research. Strong translational research program in immunotherapy and biological therapy of cancer and is developing a gene therapy program focused primarily on hematologic malignancies. Leader in minority participation in clinical studies. More than 30 percent of participants are minorities, far exceeding the U.S. average of less than 10 percent. Partnership with the state of Maryland through the Maryland Cigarette Restitution Fund Program, which provides funds